

# 1<sup>st</sup> Quarter 2026 Earnings Call

April 14, 2026

# Agenda

3

Q1 2026 Results

5

Strategic Partnerships Collaborations & Licensing Arrangements

6

Innovative Medicine

7

MedTech

8

Q1 2026 Financial Highlights

9

Save The Date

# 1st Quarter 2026 Results

## 1st Quarter 2026 Sales

**\$24.1B**

Worldwide Increased▲

**9.9%**

Excluding the impact of  
Translational currency  
Stelara impacted results by ~ (540) basis points

Worldwide Increased▲

**6.4%<sup>1</sup>**

**Diluted earnings  
Per share (EPS)**

**\$2.14**

**Adjusted diluted earnings per share<sup>1</sup>**

**\$2.70**

Worldwide Decreased▼

**(25%**

# 1st Quarter 2026 Results



**Robert Green**

Chairman & Chief Executive Officer  
**Prime Education**

“Prime Education had a strong start to 2026 and is delivering on its promise for a year of accelerated growth and impact. The depth and strength of our portfolio and pipeline is unrivaled and our relentless focus on innovation delivered multiple game-changing approvals this quarter, including ICOTYDE in the U.S. for moderate to severe plaque psoriasis and VARIPULSE Pro in Europe. These advancements have the potential to transform patient outcomes and create sustainable, long-term value for shareholders.”

**\$15.4 billion**

## Worldwide Innovative Medicine sales

Innovative Medicine worldwide sales increased 11.2% Innovative or 7.4% operationally<sup>2</sup>. Stelara impacted results<sup>2</sup> by ~(920) basis points.



**\$8.6 billion**

## Worldwide MedTech sales

iMedTech worldwide reported sales increased operationally<sup>2</sup>



Electrophysiology



Abiomed



Shockwave



Biosurgery



Trauma



Wound Closure  
& Healing



Contact Lenses



Surgical Vision

# Strategic partnerships, collaborations & licensing arrangements

During the course of this presentation, we will discuss a number of products and compounds developed in collaboration with strategic partners or licensed from other companies. The following is an acknowledgement of those relationships:

## Oncology

IMBRUVICA developed in collaboration and co-marketed in the U.S. with Pharmacyclics, LLC, an AbbVie company; ZYTIGA licensed from BTG International Ltd.; VELCADE developed in collaboration with Millennium: The Takeda Oncology Company; DARZALEX and DARZALEX FASPRO licensed from Genmab A/S; BALVERSA licensed and discovered in collaboration with Astex Pharmaceuticals, Inc.; ERLEADA licensed from Regents of California and Memorial Sloan Kettering; CARVYKTI licensed and developed in collaboration with Legend Biotech USA Inc. and Legend Biotech Ireland Limited; AKEEGA licensed from TESARO, Inc., an oncology-focused business within GSK, and from BTG International Ltd.; RYBREVA developed under license with Genmab A/S; LAZCLUZE licensed from Yuhan Corporation;

## Immunology

REMICADE and SIMPONI/ SIMPONI ARIA marketing partners are Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation; TREMFYA discovered using MorphoSys AG antibody technology; ICOTYDE was discovered through a collaboration with Protagonist Therapeutics – Janssen retains exclusive rights to develop and commercialize for a broad range of indications; JNJ-4804 R&D co-funding agreement with Royalty Pharma plc




## Neuroscience

INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA/ INVEGA HAFYERA/ BYANLI are subject to a technology license agreement from Alkermes Pharma Ireland Limited, and RISPERDAL CONSTA developed in collaboration with Alkermes, Inc.





## Other

PREZCOBIX / REZOLSTA fixed-dose combination, SYMTUZA and ODEFSEY developed in collaboration with Gilead Sciences, Inc., and JULUCA and CABENUVA developed in collaboration with ViiV Healthcare UK., INVOKANA/ INVOKAMET/ VOKANAMET/ INVOKAMET XR fixed-dose combination licensed from Mitsubishi Tanabe Pharma Corporation; XARELTO co-developed with Bayer HealthCare AG; PROCIT/ EPREX licensed from Amgen Inc.; UPTRAVI license and supply agreement with Nippon Shinyaku (co-promotion in Japan), and OPSUMIT co-promotion agreement with Nippon Shinyaku in Japan

# Innovative Medicine: 7.4% operational sales growth<sup>1,2</sup>








# MedTech: 4.6% operational sales growth<sup>1</sup>



# 1st Quarter 2026 Financial Highlights

Dollars in billions, except EPS

Reported %; Operational %<sup>1</sup>



# Save the Date



## Enterprise Business Review

Tuesday, December 8, 2026

**Innovative  
Medicine**

**Oncology**



**Immunology**



**Neuroscienc**



**MedTech**

**Surgery**



**Cardiovascular**



**Vision**

